Difference between revisions of "PEComa"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "=Guidelines=" to "=Guidelines= '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.'''") |
Warner-admin (talk | contribs) m (Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines") |
||
| Line 14: | Line 14: | ||
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.''' | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.''' | ||
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
| − | *''NCCN does not have guidelines at this granular level; please see [https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf NCCN Guidelines - Soft Tissue Sarcoma].'' | + | *''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf NCCN Guidelines - Soft Tissue Sarcoma].'' |
=All lines of therapy= | =All lines of therapy= | ||
==nab-Sirolimus monotherapy {{#subobject:a9367b|Regimen=1}}== | ==nab-Sirolimus monotherapy {{#subobject:a9367b|Regimen=1}}== | ||
Revision as of 19:50, 29 November 2023
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Soft Tissue Sarcoma.
All lines of therapy
nab-Sirolimus monotherapy
Regimen
| FDA-recommended dose |
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Wagner et al. 2021 (AMPECT) | 2016-2018 | Phase 2 (RT) |
Targeted therapy
- Sirolimus protein-bound particles (Fyarro) 100 mg/m2 IV once per day on days 1 & 8
21-day cycles
References
- AMPECT: Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Grigorian B, Schmid AN, Hou S, Harris K, Kwiatkowski DJ, Desai NP, Dickson MA. nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. J Clin Oncol. 2021 Nov 20;39(33):3660-3670. Epub 2021 Oct 12. link to original article contains dosing details in manuscript link to PMC article PubMed NCT02494570